NKL 22

NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC50 of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2/4/5/7/8 (IC50≥1.59 μM) . NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice[1][2][3].

Product Specifications

CAS Number

[537034-15-4]

UNSPSC

12352005

Hazard Statement

H302

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/NKL-22.html

Purity

97.26

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC=C1N)CCCCCC(NC2=CC=CC=C2)=O

Molecular Formula

C19H23N3O2

Molecular Weight

325.40

Precautions

H302

References & Citations

[1]D Herman et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol, 2006 Oct, 2 (10) :551-8.|[2]Jia H, et, al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis. 2012 May;46 (2) :351-61.|[3]Thomas EA, et, al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A. 2008 Oct 7;105 (40) :15564-9.